For Quick Alerts
For Daily Alerts

NATCO gets a boost in favourable verdict on Copaxone


NATCO Pharma has said that the US Court of Appeals for the Federal Circuit ruling, has reversed a district court's finding related to Teva's US Patent for Copaxone.

This would essentially mean that NATCO could launch the generic Copaxone - through its
marketing partner - Mylan Inc., during May 2014, subject to FDA approval. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.

The product is estimated to have clocked revenues, in USA, of about US $3.45 Billion during 2012.


Shares in Natco which closed at Rs 491 on Friday, may receive a boost when markets re-open for trading on Monday.

Read more about: natco
Story first published: Saturday, July 27, 2013, 12:25 [IST]
Company Search
Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'


We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more